Literature DB >> 12220625

Telomere maintenance in telomerase-positive human ovarian SKOV-3 cells cannot be retarded by complete inhibition of telomerase.

Yuebo Gan1, Yiqun Mo, Jeffrey Johnston, Jie Lu, M Guillaume Wientjes, Jessie L-S Au.   

Abstract

The two known mechanisms for telomere maintenance in eukaryocytes are telomerase in telomerase-positive cells and alternative lengthening of telomeres (ALT) in telomerase-negative cells. We report here that telomere maintenance in the telomerase-positive human ovarian SKOV-3 cells was not affected by inhibition of telomerase. For comparison, the effect of telomerase inhibitors on telomere maintenance in another telomerase-positive cell line (i.e. human pharynx FaDu cells) and the telomerase-negative human osteosarcoma Saos-2 cells was examined. Telomerase activity was measured using a modified telomeric repeat amplification protocol and telomere length was measured using a solution hybridization-based method and fluorescence in situ hybridization. A reverse transcriptase inhibitor (3'-azido-deoxythymidine or AZT) and an antisense against a component of human telomerase RNA (antisense hTR) were used to inhibit telomerase. FaDu and SKOV-3 cells showed comparable baseline telomerase activity. Telomerase activity in both cells was inhibited about equally by AZT (maximal inhibition of approximately 80%) and by expression of antisense hTR (complete inhibition in SKOV-3 cells and maximal inhibition of approximately 80% in FaDu cells). However, treatment with telomerase inhibitors resulted in approximately 50% telomere shortening in FaDu cells but had no effect on SKOV-3 nor Saos-2 cells. SKOV-3 cells did not show the characteristic features of ALT (i.e. heterogeneous telomere length and promyelocytic leukemia bodies), whereas these ALT features were observed in Saos-2 cells. Collectively, these results suggest the existence of a telomerase-independent mechanism of telomere maintenance in the telomerase-positive SKOV-3 cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12220625     DOI: 10.1016/s0014-5793(02)03141-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

1.  Pharmacodynamics of telomerase inhibition and telomere shortening by noncytotoxic suramin.

Authors:  Yuebo Gan; Jie Lu; Bertrand Z Yeung; Christopher T Cottage; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2014-11-26       Impact factor: 4.009

2.  Evidence of extra-telomeric effects of hTERT and its regulation involving a feedback loop.

Authors:  Serene R Lai; Amanda P Cunningham; Vu Q Huynh; Lucy G Andrews; Trygve O Tollefsbol
Journal:  Exp Cell Res       Date:  2006-10-25       Impact factor: 3.905

3.  Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age.

Authors:  Daniela Lötsch; Bahil Ghanim; Magdalena Laaber; Gabriele Wurm; Serge Weis; Stefan Lenz; Gerald Webersinke; Josef Pichler; Walter Berger; Sabine Spiegl-Kreinecker
Journal:  Neuro Oncol       Date:  2013-02-07       Impact factor: 12.300

4.  MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression.

Authors:  Bairong Xia; Huiyan Li; Shanshan Yang; Tianbo Liu; Ge Lou
Journal:  Tumour Biol       Date:  2016-01-14

5.  AZT as a telomerase inhibitor.

Authors:  Daniel E Gomez; Romina G Armando; Daniel F Alonso
Journal:  Front Oncol       Date:  2012-09-06       Impact factor: 6.244

6.  Assessing telomere length using surface enhanced Raman scattering.

Authors:  Shenfei Zong; Zhuyuan Wang; Hui Chen; Yiping Cui
Journal:  Sci Rep       Date:  2014-11-10       Impact factor: 4.379

7.  Chromosomal integration of HHV-6A during non-productive viral infection.

Authors:  Nitish Gulve; Celina Frank; Maximilian Klepsch; Bhupesh K Prusty
Journal:  Sci Rep       Date:  2017-03-30       Impact factor: 4.379

Review 8.  Telomerase in Cancer: Function, Regulation, and Clinical Translation.

Authors:  Nathaniel J Robinson; William P Schiemann
Journal:  Cancers (Basel)       Date:  2022-02-05       Impact factor: 6.639

Review 9.  The Role of Alternative Lengthening of Telomeres Mechanism in Cancer: Translational and Therapeutic Implications.

Authors:  Marta Recagni; Joanna Bidzinska; Nadia Zaffaroni; Marco Folini
Journal:  Cancers (Basel)       Date:  2020-04-11       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.